Agency Plans to Study Drug Makers' Records to See Whether Deals Delay Generics.

Reports on the plans of the United States Federal Trade Commission to investigate records of pharmaceutical companies to see whether drug industry strategies were keeping lower-cost generic drugs from patients or harming consumers. Comments from Robert Pitofsky, the commission chairman; Purpose of the commission's effort; Implication of the Hatch-Waxman.